MedTrace Logo

Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

NCT03790800 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2425

Last updated 2025-03-26

No results posted yet for this study

Summary

A multicentre, ambulance-delivered, prospective, randomized, open-label, blinded endpoint (PROBE) study to assess the effects of hyperacute intensive blood pressure (BP) lowering initiated in ambulance setting on (i) functional outcome in patients with acute stroke (ii) safety in patients with confirmed acute stroke and other conditions that were initially suspected as acute stroke (i.e. stroke mimic).

Conditions

  • Stroke, Acute
  • Cerebrovascular Disorders

Interventions

DRUG

urapidil

A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.

Sponsors & Collaborators

  • Shanghai East Hospital, China

    collaborator UNKNOWN

  • First Affiliated Hospital of Chengdu Medical College, China

    collaborator UNKNOWN

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China

    collaborator UNKNOWN

  • The George Institute for Global Health, China

    lead OTHER

Principal Investigators

  • Craig Anderson · The George Institute for Global Health, China

  • Lili Song · The George Institute for Global Health, China

  • Gang Li · Shanghai East Hospital, China

  • Jie Yang · Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China

  • Yapeng Lin · The First Affliated Hospital of Chengdu Medical College, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-20
Primary Completion
2023-11-23
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03790800 on ClinicalTrials.gov